Second-Line and Subsequent Therapies after Atezolizumab Plus Bevacizumab Treatment in Hepatocellular Carcinoma: A Multicenter Prospective Cohort Study

Background/Aims : Optimal second-line (2L) and third-line (3L) systemic therapies after first-line (1L) atezolizumab plus bevacizumab (AtezoBev) for advanced hepatocellular carcinoma (HCC) remain undefined. This prospective multicenter study evaluated the efficacy and safety of various 2L and 3L sys...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Yuri Cho, Jeong-Hoon Lee, Baek-Yeol Ryoo, Ho Yeong Lim, Dong Eun Lee, Bo Hyun Kim, Joong-Won Park
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Gastroenterology Council for Gut and Liver 2026-07-01
coleção:	Gut and Liver
Assuntos:	hepatocellular carcinoma atezolizumab plus bevacizumab second-line treatment lenvatinib sorafenib
Acesso em linha:	http://gutnliver.org/journal/view.html?doi=10.5009/gnl250532
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!